Optimisation of immunosuppressive therapy using pharmacokinetic principles.
Clinical experience with immunosuppressive therapy is more extensive in the area of preventing the rejection of transplanted organs than in the treatment of autoimmune diseases. Among the many pharmacological agents presently in use, only prednisone (or methylprednisolone) and cyclosporin require dosage individualisation. Sources of interindividual variability in the pharmacokinetics of prednisone have been identified and are guiding the selection of individual dosage rates. As an alternative, a single timed concentration can determine an apparent value for prednisone clearance from which an individual dosage can be calculated. In contrast, numerous sources of inter- and intraindividual variability in cyclosporin pharmacokinetics prevent the easy selection of safe and effective starting dose rates. Indeed, test doses of cyclosporin followed by series of blood samples and the calculation of individual pharmacokinetic parameters are needed to assure successful immunosuppression right from the start. Furthermore, only continued monitoring sustains immunotherapy vis-à-vis intraindividual variability and a narrow therapeutic range of cyclosporin concentrations.
Grevel
J
J
Department of Pharmacology, University of Texas Medical School, Houston.
D000328:Adult; D002648:Child; D003524:Cyclosporins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004347:Drug Interactions; D016903:Drug Monitoring; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008775:Methylprednisolone / Q000008:administration & dosage / Q000493:pharmacokinetics; D011239:Prednisolone / Q000008:administration & dosage / Q000493:pharmacokinetics*
D003524:Cyclosporins; D007166:Immunosuppressive Agents; D011239:Prednisolone; D008775:Methylprednisolone